ArticleAdvances in laboratory medicine2026
High sensitive troponin T elevation in an oncology patient on treatment with Pembrolizumab.
Article in Advances in laboratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Troponins are a complex of three proteins that play a key role in the contraction of striated muscles. Currently, cardiac troponins T (cTnT) and I (cTnI) are the best biomarkers for acute myocardial infarction (AMI) diagnostic. Case presentation: Immune-mediated toxicity due to Pembrolizumab was suspected in a 70-year-old male patient with gastric adenocarcinoma. To confirm this, creatine kinase (CK) and high sensitivity troponin T (hs-cTnT) analysis was carried out, giving values above the reference range. While CK normalized over time, hs-cTnT levels remained high. Before opting to perform an endomyocardial biopsy, high-sensitive troponin I (hs-cTnI) was measured, yielding a normal value. Due to discrepancies in troponin levels, a standard protocol was followed to confirm the presence of analytical interferences, that was negative. Conclusions: The discrepancy observed between both troponin levels, and the absence of analytical interference, led us to exclude cardiac damage in our patient. So, the most probable cause of elevated cTnT was muscle involvement. This case highlights the importance of confirming troponin results using an alternative assay to rule out limited specificity and emphasizes the need for accessible tools to identify potential analytical interferences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.